An investigation on behalf of investors in NASDAQ:CLLS shares over potential securities laws violations by Cellectis SA and certain of its directors and officers was announced.
Investors who purchased shares of Cellectis SA (ADR) (NASDAQ:CLLS), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Cellectis SA (ADR) (NASDAQ:CLLS) concerning whether a series of statements by Cellectis SA (ADR) (NASDAQ:CLLS regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On September 5, 2017, Cellectis SA announced the U.S. Food and Drug Administration’s suspension of two early-stage studies for the Company’s experimental blood cancer treatment UCART123, following the death of a patient. Shares of Cellectis SA (ADR) (NASDAQ:CLLS) declined on September 5, 2017 to $23.89 per share.
Those who purchased NASDAQ:CLLS shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego